Acceder

Bibliografías temáticas / Idiopathic pulmonary fibrosi / Artículos de revistas

Artículos de revistas sobre el tema "Idiopathic pulmonary fibrosi"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Idiopathic pulmonary fibrosi.

Autor: Grafiati

Publicado: 14 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Idiopathic pulmonary fibrosi".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Lettieri, Christopher J., Ganesh R. Veerappan, Donald L. Helman, Charles R. Mulligan y Andrew F. Shorr. "Safety of Surgical Lung Biopsy in Suspected Idiopathic Pulmonary Fibrosi". Chest 124, n.º 4 (enero de 2003): 116S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.116s.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Plataki, Maria, Anastassios Koutsopoulos, John Drossitis, George Delides, Nikolaos M. Siafakas y Demosthenes Bouros. "Expression of Apoptosis-Regulatory Genes in Epithelial Cells in Patients With Idiopathic Pulmonary Fibrosi". Chest 124, n.º 4 (enero de 2003): 192S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.192s-b.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Bell, Amanda M., Steven D. Nathan, Andrew F. Shorr, Scott D. Barnett y Donald L. Helman. "The Effect of Interferon Alone vs Interferon Plus Corticosteroids in Patients With Idiopathic Pulmonary Fibrosi". Chest 124, n.º 4 (enero de 2003): 117S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.117s-a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

NS, Mahesh, Sadanand C. D y Durga Lawande. "Clinical Profile of Idiopathic Pulmonary Fibrosis". Academia Journal of Medicine 2, n.º 2 (24 de julio de 2019): 86–89. http://dx.doi.org/10.21276/ajm.2019.2.2.22.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

N, Mahesh, Sadanand C. D y Durga Lawande. "Management of Idiopathic Pulmonary Fibrosis Cases at a Tertiary Care Hospital". Academia Journal of Medicine 2, n.º 2 (24 de julio de 2019): 90–95. http://dx.doi.org/10.21276/ajm.2019.2.2.23.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Nakanishi, Yu, Yasushi Horimasu, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto et al. "IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis". PLOS ONE 16, n.º 6 (4 de junio de 2021): e0252594. http://dx.doi.org/10.1371/journal.pone.0252594.

Texto completo

Resumen

Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow. To identify novel biomarkers that can support the diagnosis and/or prognostic prediction of idiopathic pulmonary fibrosis, we performed gene expression analysis, and the mRNA of interleukin-18 binding protein was increasingly expressed in patients with idiopathic pulmonary fibrosis compared with healthy controls. Therefore, we hypothesized that the interleukin-18 binding protein can serve as a diagnostic and/or prognostic biomarker for idiopathic pulmonary fibrosis. We investigated the expression of interleukin-18 binding protein in lung tissue, bronchoalveolar lavage fluid, and serum. Additionally, the correlation between interleukin-18 binding protein expression levels and the extent of fibrosis was investigated using mouse models of lung fibrosis induced by subcutaneous bleomycin injections. Serum interleukin-18 binding protein levels were significantly higher in idiopathic pulmonary fibrosis patients (5.06 ng/mL, interquartile range [IQR]: 4.20–6.35) than in healthy volunteers (3.31 ng/mL, IQR: 2.84–3.99) (p < 0.001). Multivariate logistic regression models revealed that the correlation between serum interleukin-18 binding protein levels and idiopathic pulmonary fibrosis was statistically independent after adjustment for age, sex, and smoking status. Multivariate Cox proportional hazard models revealed that serum interleukin-18 binding protein levels were predictive of idiopathic pulmonary fibrosis disease prognosis independent of other covariate factors (hazard ratio: 1.655, 95% confidence interval: 1.224–2.237, p = 0.001). We also demonstrated a significant positive correlation between lung hydroxyproline expression levels and interleukin-18 binding protein levels in bronchoalveolar lavage fluid from bleomycin-treated mice (Spearman r = 0.509, p = 0.004). These results indicate the utility of interleukin-18 binding protein as a novel prognostic biomarker for idiopathic pulmonary fibrosis.

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Gavrysyuk, V. K., Y. O. Dziublyk, E. O. Merenkova, O. V. Strafun y O. V. Bychenko. "PROGRESSIVE PULMONARY FIBROSIS IN LIGHT OF THE ATS/ERS/JRS/ALAT 2022 CLINICAL GUIDELINES". Ukrainian Pulmonology Journal 30, n.º 4 (2022): 51–57. http://dx.doi.org/10.31215/2306-4927-2022-30-4-51-57.

Texto completo

Resumen

Idiopathic pulmonary fibrosis – is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in 50 years and older patients, limited to the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). In 2000 American thoracic society (ATS) and European respiratory society (ERS) published the first international; statement on diagnosis and treatment of IPF American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. In 2011 there was published a new statement on diagnosis and treatment of IPF, approved by Japan respiratory society (JTS) and Latin American thoracis society (ALTS) – An Official ATS/ERS/JRS/AL : Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. In 2015 section “Treatment” and in 2018 section “Diagnosis” were revised. It is known that in part of patients with such interstitial lung diseases (ILD) as idiopathic interstitial pneumonia, systemic sclerosis, pneumoconiosis, chronic hypersensitivity pneumonitis, sarcoidosis the disease may acquire a progressive uncontrolled development with the combination of symptoms called progressive pulmonary fibrosis (PPF). At the same time the results of successful use of antifibrotic therapy have been published recently (SENSCIS, INBUILD studies). All this provided the rationale for extended indications for use of antifibrotic therapy to cover other ILDs with the features of PPF. In this connection, ATS, ERS, JRS and ALAT experts published in May 2022 An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults, in which along with the partial changes regarding the principles of diagnosis and treatment of IPF, the definition, diagnosis criteria and management of PPF due to other fibrosing ILDs were presented. The article presents the major statements of new guideline regarding the terminology, diagnosis and treatment of PPF. Key words: progressive pulmonary fibrosis, definition, diagnosis criteria, treatment.

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Rawahi, Yasmeen. "Pirfenidone Experience in Idiopathic Pulmonary Fibrosis at a Tertiary Hospital in Oman". Journal of Thoracic Disease and Cardiothoracic Surgery 1, n.º 1 (12 de junio de 2020): 01–06. http://dx.doi.org/10.31579/2693-2156/001.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Baddini-Martinez, José, Bruno Guedes Baldi, Cláudia Henrique da Costa, Sérgio Jezler, Mariana Silva Lima y Rogério Rufino. "Update on diagnosis and treatment of idiopathic pulmonary fibrosis". Jornal Brasileiro de Pneumologia 41, n.º 5 (octubre de 2015): 454–66. http://dx.doi.org/10.1590/s1806-37132015000000152.

Texto completo

Resumen

Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of unknown etiology, which is associated with a progressive decrease in pulmonary function and with high mortality rates. Interest in and knowledge of this disorder have grown substantially in recent years. In this review article, we broadly discuss distinct aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We list the current diagnostic criteria and describe the therapeutic approaches currently available, symptomatic treatments, the action of new drugs that are effective in slowing the decline in pulmonary function, and indications for lung transplantation.

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Averyanov, A. V. y V. N. Lesnyak. "FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS". Journal of Clinical Practice 7, n.º 4 (15 de diciembre de 2016): 58–65. http://dx.doi.org/10.17816/clinpract7458-65.

Texto completo

Resumen

The second part of the analytical review devoted to features of the clinical course and diagnosis of idiopathic pulmonary fibrosis. Special attention is paid to the specific CT symptoms allows diagnosis without lung biopsy. Current approaches to invasive diagnostics and perspectives of cryoprobe are discussed.

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Averyanov, A. V. "FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS". Journal of Clinical Practice 7, n.º 3 (15 de septiembre de 2016): 73–76. http://dx.doi.org/10.17816/clinpract7373-76.

Texto completo

Resumen

In this paper we try to present the current state of knowledge of the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), and to express our view on the problems and their solution, without which it is very difficult to improve the quality of medical care for IPF-patients in Russia.

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Ricci, Francesca, Luca Pugliese, Armando Ugo Cavallo, Marco Forcina, Vincenzo De Stasio, Matteo Presicce, Federica Di Tosto et al. "Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis". Acta Radiologica 61, n.º 2 (25 de junio de 2019): 204–18. http://dx.doi.org/10.1177/0284185119857435.

Texto completo

Resumen

Idiopathic pulmonary fibrosis (IPF) represents a condition included in the heterogeneous group of interstitial lung diseases without known causes. The recent ATS/ERS/JRS/ALAT guidelines and the white paper published by the Fleischner Society have well-defined diagnosis and management of idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis management is complex because it is also influenced by several co-morbidities and complications. The new frontier in idiopathic pulmonary fibrosis is represented by the effort to understand the complex mechanism of the pathogenesis and progression of disease in order to predict several consequences and co-morbidities. In our review, we tried to distinguish co-morbidities from complications of idiopathic pulmonary fibrosis. In each complication, we have reviewed the existing literature and we have emphasized the complex pathobiological pathway which links the progression of idiopathic pulmonary fibrosis to the development of the complication itself. For every co-morbidity, we tried to identify share common risk factors which explain the coexistence of idiopathic pulmonary fibrosis with its co-morbidities. We then analyzed high-resolution computed tomography (CT) aspects of co-morbidities and complications of idiopathic pulmonary fibrosis that the radiologist should be aware of. In this review, we focused on the role of high-resolution CT imaging in the evaluation of co-morbidities and complications in idiopathic pulmonary fibrosis because their early diagnosis and treatment could change the prognosis in patients with idiopathic pulmonary fibrosis. We have also pointed out that in some cases the final combined quantitative CT tools and conventional visual CT score would allow to get an accurate analysis and quantification of disease progression, co-morbidities, and complications of idiopathic pulmonary fibrosis in order to improve staging systems in idiopathic pulmonary fibrosis.

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Bargagli, Elena, Rosa Metella Refini, Miriana d’Alessandro, Laura Bergantini, Paolo Cameli, Lorenza Vantaggiato, Luca Bini y Claudia Landi. "Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis". International Journal of Molecular Sciences 21, n.º 16 (7 de agosto de 2020): 5663. http://dx.doi.org/10.3390/ijms21165663.

Texto completo

Resumen

Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New findings, starting from our proteomics studies on IPF, suggest that systemic involvement with altered molecular mechanisms and metabolic disorder is an underlying cause of fibrosis. The role of metabolic dysregulation in the pathogenesis of IPF has not been extensively studied, despite a recent surge of interest. In particular, our studies on bronchoalveolar lavage fluid have shown that the renin–angiotensin–aldosterone system (RAAS), the hypoxia/oxidative stress response, and changes in iron and lipid metabolism are involved in onset of IPF. These processes appear to interact in an intricate manner and to be related to different fibrosing pathologies not directly linked to the lung environment. The disordered metabolism of carbohydrates, lipids, proteins and hormones has been documented in lung, liver, and kidney fibrosis. Correcting these metabolic alterations may offer a new strategy for treating fibrosis. This paper focuses on the role of metabolic dysregulation in the pathogenesis of IPF and is a continuation of our previous studies, investigating metabolic dysregulation as a new target for fibrosis therapy.

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Cottin, Vincent, Nikhil A. Hirani, David L. Hotchkin, Anoop M. Nambiar, Takashi Ogura, María Otaola, Dirk Skowasch et al. "Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases". European Respiratory Review 27, n.º 150 (21 de diciembre de 2018): 180076. http://dx.doi.org/10.1183/16000617.0076-2018.

Texto completo

Resumen

Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, decreased quality of life and, potentially, early death. Idiopathic pulmonary fibrosis may be regarded as a model for other progressive-fibrosing ILDs. Here we focus on other ILDs that may present a progressive-fibrosing phenotype, namely idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, connective tissue disease-associated ILDs (e.g.rheumatoid arthritis-related ILD), fibrotic chronic hypersensitivity pneumonitis, fibrotic chronic sarcoidosis and ILDs related to other occupational exposures. Differential diagnosis of these ILDs can be challenging, and requires detailed consideration of clinical, radiological and histopathological features. Accurate and early diagnosis is crucial to ensure that patients are treated optimally.

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Jeldres, Alejandro y Gonzalo Labarca. "Is nintedanib effective for idiopathic pulmonary fibrosis?" Medwave 17, Suppl2 (18 de marzo de 2017): e6918-e6918. http://dx.doi.org/10.5867/medwave.2017.6918.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Shumar, John N., Abhimanyu Chandel y Christopher S. King. "Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD". Journal of Clinical Medicine 10, n.º 11 (25 de mayo de 2021): 2285. http://dx.doi.org/10.3390/jcm10112285.

Texto completo

Resumen

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Two antifibrotic medications, nintedanib and pirfenidone, have been approved for use in patients with idiopathic pulmonary fibrosis. Recently completed randomized controlled trials have demonstrated the clinical efficacy of antifibrotic therapy in patients with PF-ILD. The validation of efficacy of antifibrotic therapy in PF-ILD has changed the treatment landscape for all of the fibrotic lung diseases, providing a new treatment pathway and opening the door for combined antifibrotic and immunosuppressant drug therapy to address both the fibrotic and inflammatory components of ILD characterized by mixed pathophysiologic pathways.

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Swigris, Jeffrey, Katelyn Cutts, Natalia Male, Michael Baldwin, Klaus B. Rohr y Donald M. Bushnell. "The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease". ERJ Open Research 7, n.º 2 (11 de marzo de 2021): 00145–2020. http://dx.doi.org/10.1183/23120541.00145-2020.

Texto completo

Resumen

The Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire was developed with substantial input from patients with idiopathic pulmonary fibrosis (IPF) to assess symptoms and health-related quality of life (HRQoL). Because IPF is the prototypical chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, we expanded applicability of the L-IPF by deleting the word “idiopathic”, creating the L-PF (Living with Pulmonary Fibrosis) questionnaire, and then assessed its relevance among patients with progressive fibrosing ILDs in one-to-one interviews.Patients in the USA and Germany with any progressive fibrosing ILD other than IPF were asked about their disease and symptoms, completed the 44-item L-PF questionnaire (comprising two modules that assess symptoms and impacts of disease) and then answered a series of debriefing questions. Interviews were recorded, transcribed and coded for qualitative content analysis.20 patients were interviewed, but time constraints meant not all were asked about all items. The most frequent diagnoses were rheumatoid arthritis-associated ILD (25%) and mixed connective tissue disease-associated ILD (20%). Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath (19 out of 20 patients), cough (19 out of 20) and fatigue (18 out of 20). Most patients endorsed impacts of progressive fibrosing ILD on activities of daily living, physical well-being, sleep, emotional well-being, and social aspects of their lives. Most patients had an overall positive impression of the Symptoms module and understood items as intended. All seven patients asked understood the items of the Impacts module.The L-PF contains concepts relevant and important to patients with progressive fibrosing ILD, and items are understood as intended.

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Morrow, Lee E., Daniel Hilleman y Mark A. Malesker. "Management of patients with fibrosing interstitial lung diseases". American Journal of Health-System Pharmacy 79, n.º 3 (5 de octubre de 2021): 129–39. http://dx.doi.org/10.1093/ajhp/zxab375.

Texto completo

Resumen

Abstract Purpose This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. Summary The interstitial lung diseases are a heterogenous group of parenchymal lung disorders with a common feature—infiltration of the interstitial space with derangement of the normal capillary-alveolar anatomy. Diseases characterized by fibrosis of the interstitial space are referred to as the fibrosing interstitial lung diseases and often show progression over time: idiopathic pulmonary fibrosis is the most common fibrotic interstitial lung disease. Historically, therapies for fibrosing lung diseases have been limited in number, questionable in efficacy, and associated with potential harms. Food and Drug Administration (FDA) approval of the antifibrotic agents nintedanib and pirfenidone for idiopathic pulmonary fibrosis in 2014 heralded an era of reorganization of therapy for the fibrotic interstitial lung diseases. Subsequent investigations have led to FDA approval of nintedanib for systemic sclerosis–associated interstitial lung disease and interstitial lung diseases with a progressive phenotype. Although supportive care and pulmonary rehabilitation should be provided to all patients, the role(s) of immunomodulators and/or immune suppressing agents vary by the underlying disease state. Several agents previously used to treat fibrotic lung diseases (N-acetylcysteine, anticoagulation, and pulmonary vasodilators) lack efficacy or cause harm. Conclusion With the introduction of effective pharmacotherapy for fibrosing interstitial lung disease, pharmacists have an increasingly important role in the interdisciplinary team managing these patients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Avdeev, S. N. "Idiopathic pulmonary fibrosis". Russian Pulmonology 25, n.º 5 (1 de enero de 2015): 600–612. http://dx.doi.org/10.18093/0869-0189-2015-25-5-600-612.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Man, Luo y Peng Hong. "Idiopathic Pulmonary Fibrosis". Chinese Medical Journal 130, n.º 17 (septiembre de 2017): 2140–41. http://dx.doi.org/10.4103/0366-6999.213423.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Thompson, Austin B., John R. Spurzem y Stephen I. Rennard. "IDIOPATHIC PULMONARY FIBROSIS". Immunology and Allergy Clinics of North America 12, n.º 2 (mayo de 1992): 401–19. http://dx.doi.org/10.1016/s0889-8561(22)00116-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Selman, Mois??s, Victor J. Thannickal, Annie Pardo, David A. Zisman, Fernando J. Martinez y Joseph P. Lynch. "Idiopathic Pulmonary Fibrosis". Drugs 64, n.º 4 (2004): 405–30. http://dx.doi.org/10.2165/00003495-200464040-00005.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Skvortsov, Vsevolod V., Arina N. Gorbach, Elena V. Belyakova, Ekaterina M. Skvortsova y Nikita D. Matveyev. "Idiopathic pulmonary fibrosis". Meditsinskaya sestra 23, n.º 7 (2021): 42–45. http://dx.doi.org/10.29296/25879979-2021-07-09.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Skvortsov, Vsevolod Vladimirovich, Arina Nikolaevna Gorbach, Elena Vladimirovna Belyakova, Ekaterina Mikhailovna Skvortsova y Nikita Dmitrievich Matveyev. "Idiopathic pulmonary fibrosis". Meditsinskaya sestra 24, n.º 2 (2022): 16–19. http://dx.doi.org/10.29296/25879979-2022-02-04.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Avdeev, S. N. "Idiopathic pulmonary fibrosis". Consilium Medicum 19, n.º 3 (2017): 17–23. http://dx.doi.org/10.26442/2075-1753_19.3.17-23.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Gross, Thomas J. y Gary W. Hunninghake. "Idiopathic Pulmonary Fibrosis". New England Journal of Medicine 345, n.º 7 (16 de agosto de 2001): 517–25. http://dx.doi.org/10.1056/nejmra003200.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Lederer, David J. y Fernando J. Martinez. "Idiopathic Pulmonary Fibrosis". New England Journal of Medicine 378, n.º 19 (10 de mayo de 2018): 1811–23. http://dx.doi.org/10.1056/nejmra1705751.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Lynch, Joseph P., Michael C. Fishbein, Rajeev Saggar, David A. Zisman y John A. Belperio. "Idiopathic pulmonary fibrosis". Expert Review of Respiratory Medicine 1, n.º 3 (diciembre de 2007): 377–89. http://dx.doi.org/10.1586/17476348.1.3.377.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Flaherty, Kevin R., Adin-Cristian Andrei, Susan Murray, Chris Fraley, Thomas V. Colby, William D. Travis, Vibha Lama et al. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 174, n.º 7 (octubre de 2006): 803–9. http://dx.doi.org/10.1164/rccm.200604-488oc.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Antoniou, Katerina M., David M. Hansell, Michael B. Rubens, Katharina Marten, Sujal R. Desai, Nikolaos M. Siafakas, Andrew G. Nicholson, Roland M. du Bois y Athol U. Wells. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 177, n.º 2 (15 de enero de 2008): 190–94. http://dx.doi.org/10.1164/rccm.200612-1759oc.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Thannickal, Victor J. y James E. Loyd. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 178, n.º 7 (octubre de 2008): 663–65. http://dx.doi.org/10.1164/rccm.200807-1127ed.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Zisman, David A. y Steven M. Kawut. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 178, n.º 12 (15 de diciembre de 2008): 1192–93. http://dx.doi.org/10.1164/rccm.200808-1339ed.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Tierney, Lawrence. "Idiopathic Pulmonary Fibrosis". Seminars in Respiratory and Critical Care Medicine 12, n.º 03 (julio de 1991): 229–37. http://dx.doi.org/10.1055/s-2007-1006242.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Dempsey, O. J. y D. Miller. "Idiopathic pulmonary fibrosis". BMJ 347, n.º 07 4 (7 de noviembre de 2013): f6579. http://dx.doi.org/10.1136/bmj.f6579.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

Salisbury, Margaret L., Meng Xia, Yueren Zhou, Susan Murray, Nabihah Tayob, Kevin K. Brown, Athol U. Wells, Shelley L. Schmidt, Fernando J. Martinez y Kevin R. Flaherty. "Idiopathic Pulmonary Fibrosis". Chest 149, n.º 2 (febrero de 2016): 491–98. http://dx.doi.org/10.1378/chest.15-0530.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Swigris, Jeffrey J., Ware G. Kuschner, Jennifer L. Kelsey y Michael K. Gould. "Idiopathic Pulmonary Fibrosis". Chest 127, n.º 1 (enero de 2005): 275–83. http://dx.doi.org/10.1378/chest.18.4.330.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Du Bois, R. M. "Idiopathic Pulmonary Fibrosis". Annual Review of Medicine 44, n.º 1 (febrero de 1993): 441–50. http://dx.doi.org/10.1146/annurev.me.44.020193.002301.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

DOUGLAS, WILLIAM W, JAY H RYU y DARRELL R SCHROEDER. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 161, n.º 4 (abril de 2000): 1172–78. http://dx.doi.org/10.1164/ajrccm.161.4.9907002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Katzenstein, Anna-Luise A. y Jeffrey L. Myers. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 164, n.º 2 (15 de julio de 2001): 185–86. http://dx.doi.org/10.1164/ajrccm.164.2.2105010a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

KING, TALMADGE E, MARVIN I SCHWARZ, KEVIN BROWN, JANET A TOOZE, THOMAS V COLBY, JAMES A WALDRON, ANDREW FLINT, WILLIAM THURLBECK y REUBEN M CHERNIACK. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 164, n.º 6 (15 de septiembre de 2001): 1025–32. http://dx.doi.org/10.1164/ajrccm.164.6.2001056.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Thannickal, Victor. "Idiopathic Pulmonary Fibrosis". Seminars in Respiratory and Critical Care Medicine 27, n.º 6 (diciembre de 2006): 567–68. http://dx.doi.org/10.1055/s-2006-957327.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

du Bois, Roland M., Steven D. Nathan, Luca Richeldi, Marvin I. Schwarz y Paul W. Noble. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 186, n.º 8 (15 de octubre de 2012): 712–15. http://dx.doi.org/10.1164/rccm.201206-1010pp.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Kamp, David W. "Idiopathic Pulmonary Fibrosis". Chest 124, n.º 4 (octubre de 2003): 1187–90. http://dx.doi.org/10.1378/chest.124.4.1187.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Swigris, Jeffrey J. "Idiopathic Pulmonary Fibrosis*". CHEST Journal 127, n.º 1 (1 de enero de 2005): 275. http://dx.doi.org/10.1378/chest.127.1.275.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Ahmed, Ala'Eldin H. "Idiopathic Pulmonary Fibrosis". Chest 127, n.º 2 (febrero de 2005): 694. http://dx.doi.org/10.1378/chest.127.2.694.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Horowitz, Jeffrey C. y Victor J. Thannickal. "Idiopathic Pulmonary Fibrosis". Treatments in Respiratory Medicine 5, n.º 5 (2006): 325–42. http://dx.doi.org/10.2165/00151829-200605050-00004.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Lindell, Kathleen Oare y Susan S. Jacobs. "Idiopathic Pulmonary Fibrosis". AJN, American Journal of Nursing 103, n.º 4 (abril de 2003): 32–42. http://dx.doi.org/10.1097/00000446-200304000-00016.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

McDonald, John A. "Idiopathic Pulmonary Fibrosis". Chest 99, n.º 3 (marzo de 1991): 87S—93S. http://dx.doi.org/10.1378/chest.99.3_supplement.87s.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

POCHIS, WILLIAM T., ARTHUR Z. KRASNOW, B. DAVID COLLIER, MARK W. MEWISSEN, URIAS A. ALMAGRO, ROBERT S. HELLMAN y ALI T. ISITMAN. "Idiopathic Pulmonary Fibrosis". Clinical Nuclear Medicine 15, n.º 5 (mayo de 1990): 321–23. http://dx.doi.org/10.1097/00003072-199005000-00009.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Wells, Athol U., Sujal R. Desai, Michael B. Rubens, Nicole S. L. Goh, Derek Cramer, Andrew G. Nicholson, Thomas V. Colby, Roland M. du Bois y David M. Hansell. "Idiopathic Pulmonary Fibrosis". American Journal of Respiratory and Critical Care Medicine 167, n.º 7 (abril de 2003): 962–69. http://dx.doi.org/10.1164/rccm.2111053.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!